Published ahead of print on August 15, 2002, doi:10.1164/rccm.200202-155OC
Am. J. Respir. Crit. Care Med., Volume 167, Number 3, February 2003, 390-394
A more recent version of this article appeared on February 1, 2003
Submitted on February 26, 2002
Accepted on August 11, 2002
Endothelial Nitric Oxide Synthase Variants in Cystic Fibrosis Lung Disease
Hartmut Grasemann1*, Karin Storm van's Gravesande2, Rainer Buscher1, Nikola Knauer1, Eric S Silverman2, Lyle J Palmer3, Jeffrey M Drazen2, and Felix Ratjen1
1 University of Essen, Children's Hospital, Essen, Germany,
2 Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA,
3 Channing Laboratory, Brigham and Women's Hospital, Boston, MA, USA; Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA
* To whom correspondence should be addressed. E-mail: hartmutg{at}hotmail.com.
Variants in the genes encoding for the nitric oxide synthases may act as disease modifier loci in cystic fibrosis, affecting both an individual's nitric oxide level and pulmonary function. In the present study, the 894G/T variant in exon 7 of the endothelial nitric oxide synthase gene was related to exhaled nitric oxide and pulmonary function in 70 cystic fibrosis patients aged 14.8±6.9 years (mean±standard deviation), with a mean forced expiratory volume in one second of 69.4±24.8 % predicted. While there was no association between endothelial nitric oxide synthase genotypes and exhaled nitric oxide in males, nitric oxide levels were significantly higher in female cystic fibrosis patients with a 894T mutant allele, compared to female patients homozygous for the 894G wild-type allele (7.0±4.4 ppb vs. 3.6±1.9 ppb, p = 0.02). Furthermore, in female patients, colonization of airways with Pseudomonas aeruginosa was significantly (p < 0.05) less frequent when carrying a 894T mutant allele as compared to wildtype. These data suggest that the 894T variant the endothelial nitric oxide synthase gene is associated with increased airway nitric oxide formation in female CF patients, possibly affecting colonization of airways with Pseudomonas aeruginosa.
Key words: exhaled NO, pulmonary function, P. aeruginosa, association study
This article has been cited by other articles:

|
 |

|
 |
 
C. Grasemann, F. Ratjen, D. Schnabel, E. Reutershahn, U. Vester, and H. Grasemann
Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients
Eur. Respir. J.,
April 1, 2008;
31(4):
815 - 821.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Boyle
Strategies for Identifying Modifier Genes in Cystic Fibrosis
Proceedings of the ATS,
January 1, 2007;
4(1):
52 - 57.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. F. McKone, J. Shao, D. D. Frangolias, C. L. Keener, C. A. Shephard, F. M. Farin, M. R. Tonelli, P. D. Pare, A. J. Sandford, M. L. Aitken, et al.
Variants in the Glutamate-Cysteine-Ligase Gene Are Associated with Cystic Fibrosis Lung Disease
Am. J. Respir. Crit. Care Med.,
August 15, 2006;
174(4):
415 - 419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Grasemann, F. Kurtz, and F. Ratjen
Inhaled L-Arginine Improves Exhaled Nitric Oxide and Pulmonary Function in Patients with Cystic Fibrosis
Am. J. Respir. Crit. Care Med.,
July 15, 2006;
174(2):
208 - 212.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Drumm, M. W. Konstan, M. D. Schluchter, A. Handler, R. Pace, F. Zou, M. Zariwala, D. Fargo, A. Xu, J. M. Dunn, et al.
Genetic Modifiers of Lung Disease in Cystic Fibrosis
N. Engl. J. Med.,
October 6, 2005;
353(14):
1443 - 1453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Grasemann, C. Grasemann, F. Kurtz, G. Tietze-Schillings, U. Vester, and F. Ratjen
Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study
Eur. Respir. J.,
January 1, 2005;
25(1):
62 - 68.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. G. Noone, M. W. Leigh, A. Sannuti, S. L. Minnix, J. L. Carson, M. Hazucha, M. A. Zariwala, and M. R. Knowles
Primary Ciliary Dyskinesia: Diagnostic and Phenotypic Features
Am. J. Respir. Crit. Care Med.,
February 15, 2004;
169(4):
459 - 467.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Tobin
Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2003
Am. J. Respir. Crit. Care Med.,
January 15, 2004;
169(2):
277 - 287.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Mekus, B. Tummler, F. Ratjen, and H. Grasemann
Cystic Fibrosis and NOS3
Am. J. Respir. Crit. Care Med.,
January 15, 2004;
169(2):
319 - 320.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. L. Wallace, P. M. Barker, and K. W. Southern
Nasal Airway Ion Transport and Lung Function in Young People with Cystic Fibrosis
Am. J. Respir. Crit. Care Med.,
September 1, 2003;
168(5):
594 - 600.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Grasemann, K. S. van's Gravesande, R. Buscher, J. M. Drazen, and F. Ratjen
Effects of Sex and of Gene Variants in Constitutive Nitric Oxide Synthases on Exhaled Nitric Oxide
Am. J. Respir. Crit. Care Med.,
April 15, 2003;
167(8):
1113 - 1116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. Accurso and M. K. Sontag
Seeking Modifier Genes in Cystic Fibrosis
Am. J. Respir. Crit. Care Med.,
February 1, 2003;
167(3):
289 - 290.
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 American Thoracic Society
|
|
|